Differential effects of switching to integrase strand transfer inhibitors on the gut microbiota and markers of HIV disease progression.

改用整合酶链转移抑制剂对肠道菌群和 HIV 疾病进展标志物的不同影响

阅读:16
作者:Pinto-Cardoso Sandra M, Aguilar-Vargas Adriana, López-Filloy Mariana, Chávez-Torres Monserrat, Murakami-Osawara Akio, Briceño Olivia, Romero-Mora Karla, Rodríguez-Moguel Nadia, Salgado Montes de Oca Gonzalo, Ávila-Ríos Santiago
BACKGROUND: Unwanted weight gain is often reported in people living with HIV (PWH) who start on or switch to integrase strand transfer inhibitors (INSTI). Mechanisms are incompletely understood. An unintended off-target of INSTI might be the gut microbiota. METHODS: We explored the fecal microbiota of treated aviremic PWH (n = 70) who switched from efavirenz (EFV)- to a bictegravir (BIC)-based regimen. 16S rRNA sequencing, and enzyme-linked immunosorbent assays were used to characterize the fecal microbiota and quantify markers of HIV disease progression. A cohort of high-risk HIV-negative individuals (n = 18) was included to address differential effects of antiretroviral therapy (ART) on the fecal microbiota. RESULTS: This real-life cohort was predominantly male (n = 63) and mostly men who have sex with men (n = 40). All PWH were on the same antiretroviral regimen for at least 1 year; the mean time on ART was 10.83 ± 5.530 years and all had undetectable plasma viral loads (< 40 HIV-1 RNA copies/mL). PWH gained a median weight of 3.375 kg and the mean percent weight change relative to baseline was 4.32%. Seven (10%) PWH gained significant weight (> 10% relative to baseline). Switching to a BIC-based regimen had contrasting effects. PWH on BIC/FTC/TAF showed decreased microbial translocation (soluble CD14, sCD14), decreased enterocyte damage (intestinal fatty-acid binding protein, I-FABP), and increased alpha diversity (richness and shannon); all indicative of a better restoration of the gut mucosa and microbiota. Conversely, increases in sCD163, monocyte chemoattractant protein 1 (MCP-1) and decreases in adiponectin, markers linked to cardiovascular disease, insulin resistance and adiposity, were unfavorable. CONCLUSION: Our data suggest that INSTI have a less detrimental effect on the gut microbiota compared to EFV-based regimen. The link between weight gain on INSTI and the gut microbiota was not readily apparent.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。